Acadia Pharmaceuticals | ACAD - Selling And Administration Expenses


Acadia Pharmaceuticals reported $146.88M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Corcept Therapeutics USD 142.04M 14.86M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
Eisai JPY 120.4B 5.58B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
J&J USD 6.25B 168M Sep/2026
Moderna USD 282M 66M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Prothena USD 10.9M 1.77M Jun/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026